联合检测CEA、NSE和CYFRA21-1在肺癌诊断中的价值

Objective To investigate the diagnostic value of Joint determination of CEA,NSE and CYFRA21-1 in serum from patients with lung cancer.Methods Detected the CEA、NSE、CYFRA21-1 in different type patients with lung cancer.Results In lung cancer group,the levels of CEA,NSE and CYFRA21-1 were significantly higher than those group of benign lung disease (P<0.05).The sensitivity of joint measurement CEA,NSE and CYFRA21-1 was significantly higher than that of each tumor marker(P<0.05).Conclusion Joint measurement of CEA,NSE and CYFRA21-1 is helpful to diagnosis of lung cancer.     

联合检测CEA、NSE和CYFRA21-1在肺癌诊断中的价值

Objective To investigate the diagnostic value of Joint determination of CEA,NSE and CYFRA21-1 in serum from patients with lung cancer.Methods Detected the CEA、NSE、CYFRA21-1 in different type patients with lung cancer.Results In lung cancer group,the levels of CEA,NSE and CYFRA21-1 were significantly higher than those group of benign lung disease (P<0.05).The sensitivity of joint measurement CEA,NSE and CYFRA21-1 was significantly higher than that of each tumor marker(P<0.05).Conclusion Joint measurement of CEA,NSE and CYFRA21-1 is helpful to diagnosis of lung cancer.     

肿瘤标志物DJ-1、NSE、CYFRA21-1和CEA联合检测在肺癌诊断中的应用价值

目的 探讨肿瘤标志物D J-1蛋白(DJ-1)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段21-1 (CYFRA21-1)及癌胚抗原(CEA)在肺癌患者血清中的水平以及在肺癌诊断中的价值.方法 采用酶联免疫吸附法(ELISA)检测血清DJ-1蛋白,采用电化学发光法(ECLIA)检测血清NSE、CYFRA21-1和CEA水平,比较分析肺癌组、肺部良性疾病组和健康对照组的各60例病例.结果 肺癌组的4种血清肿瘤标志物水平均高于肺部良性疾病组和健康对照组,差异有统计学意义(P＜0.01);肺癌病理类型中鳞癌中有较高的DJ-1和CYFRA21-1水平,腺癌中有较高的CEA水平,而小细胞癌中有较高的NSE水平;以上4种肿瘤标志物联合检测肺癌的诊断价值最高,灵敏度为85％,特异度为78.3％,约登指数达到0.63.结论 DJ-1、NSE、CYFRA21-1及CEA联合检测对肺癌的诊断有一定的价值,可以作为高危人群初步筛查的指标.     

CEA、NSE、CYFRA21-1联合检测在肺癌诊断中的价值

目的分析CEA、NSE、CYFRA21-1联合检测在肺癌诊断中的价值。方法择取2016年1月-2017年10月我院胸外科住院者为研究对象,分为肺癌组254例以及良性病变组74例,肺癌组再细分为鳞癌、腺癌、小细胞癌以及其他。开展CEA、NSE、CYFRA21-1联合检测,分析结果。结果肺癌组的CEA以及CYFRA21-1明显比良性病变组高,P0.05。NSE无明显差异,P0.05。鳞癌者CEA以及CYFRA21-1、NSE比腺癌高,P0.05。腺癌的CEA以及CYFRA21-1比良性组高,P0.05。小细胞癌者的CYFRA21-1、NES比良性组高,P0.05。不同类型的肺癌患者3种肿瘤标志物的单项检出率差异均有统计学意义(P0.05)。鳞癌、腺癌、小细胞肺癌阳性检出率最高的肿瘤标志物分别对应的是CYFRA21-1(81.0%)、CEA(55.3%)、NSE(77.8%)。肺癌组3项肿瘤标志物阳性率都高于良性病变组,差异均具有统计学意义(P0.05)。且CEA、NSE、CYFRA21-1肿瘤标志物联合检测的阳性率为77.2%,明显高于任何一单项的检测,差异均具有统计学意义(P0.05)。结论肺癌患者血清内CEA、NSE、CYFRA21-1均呈现出上升趋势,联合检测的阳性率明显升高,开展联合检测,有助于甄别肺癌,可以为临床制定治疗方案提供现实依据。     

血清CEA、NSE、CYFRA21-1联合检测对肺癌诊断价值的探讨

探索血清肿瘤标志物癌胚抗原、神经元特异性烯醇化酶、ＣＹＦＲＡ２１－１联合检测在肺癌诊断中的临床价值。方法采用放射免疫法测定９２例肺癌、２３８例良性病和３３例健康人血清中ＣＥＡ、ＮＳＥ、ＣＹＦＲＡ２１－１的水平。     

联合检测血清IGF-1、CEA、CYFRA21-1、NSE、CA199在肺癌诊治中的应用

目的探讨血清胰岛素样生长因子（IGF-1）、癌胚抗原（CEA）、细胞角蛋白19片段（CYFRA21-1）、神经特异性烯醇酶（NSE）、糖类蛋白19-9（CA19-9）联合检测在肺癌诊治中的具体应用价值。方法对98例肺癌组患者治疗前后,46例肺良性病变组患者,42例健康组受检者使用化学发光免疫分析法检测血清5项肿瘤标志物的表达水平,并进行比较分析。结果肺癌组患者血清5项肿瘤标志物均明显高于肺良性病变组和健康组（P〈0.05）。肺癌细患者治疗后血清5项肿瘤标志物水平明显下降（P〈0.05）。肺癌组中Ⅲ/Ⅳ期患者血清5项肿瘤标志物含量均明显高于Ⅰ/Ⅱ期（P〈0.05）。腺癌中CEA表达水平明显高于小细胞肺癌和鳞癌（P〈0.05）,小细胞肺癌中NSE表达水平明显高于腺癌和鳞癌（P〈0.05）,鳞癌中CYFRA21-1表达水平明显高于小细胞肺癌和腺癌（P〈0.05）。联合检测血清5项肿瘤标志物对肺癌的效能最高为0.986。结论肿瘤标志物在肺癌疾病的发展过程中表现出一定的差异性,特别是多项指标的联合检测对于肺癌的诊断、分期及疗效判定具有一定的临床应用价值。     

肿瘤标志物CEA、NSE、CYFRA21-1联合检测在肺癌诊断中的应用

目的:探讨肿瘤标志物CEA、NSE、CYFRA21-1联合检测在肺癌诊断及鉴别诊断中的应用价值.方法:采用电化学发光法检测68例肺癌患者血清中癌胚抗原(CEA)、神经特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)的含量,并与50例肺部良性疾病患者和50例健康者进行对比分析.结果:肺癌患者三种血清肿瘤标志物检测水平中CEA、NSE明显高于肺部良性疾病组和健康对照组,差异有显著意义(P＜0.01).CYFRA21-1在非小细胞肺癌(NSCLC)的鳞癌中阳性率最高,为62.5%;CEA在腺癌中阳性率最高,为73.5%;NSE则在肺小细胞癌(SCLC)中最高,为66.7%.CYFRA21-1、CEA、NSE在肺癌中的检测率分别为41.2%、55.9%、42.6%.三项标志物联合检测敏感性提高到76.5%,而特异性(90.0%)无明显下降.结论:血清肿瘤标志物CEA、NSE和CYFRA21-1联合检测可明显提高肺癌诊断的阳性率;联合检测对诊断肺癌具有较高的临床应用价值.     

血清CEA、ProGRP、CYFRA21-1及β2-MG联合检测在肺癌诊断中的意义

目的:探讨肿瘤标志物癌胚抗原(CEA)、胃泌素释放肽前体(Pro-GRP)、细胞角蛋白19(CYFRA21-1)及β2微球蛋白(β2-MG)水平的联合检测对肺癌临床诊断的价值。方法:分别采用电化学发光法、ELISA法和免疫浊度法测定115例肺癌、41例良性肺病患者和50例健康献血员的血清CEA、Pro-GRP、CYFRA21-1及β2-MG水平并作对比分析。结果:肺癌组血清CEA、Pro-GRP、CYFRA21-1及β2-MG的阳性检出率分别为53.9%、47.0%、61.7%、43.5%,明显高于良性肺病组(7.3%、2.4%、9.8%、12.2%)和健康对照组(4.0%、2.0%、6.0%、12.0%)(P<0.01);患者血清中的CEA、Pro-GRP、CYFRA21-1及β2-MG水平和阳性率随着临床分期升高而呈上升趋势,但差异无显著性(P>0.05);肺癌患者血清肿瘤标志物的阳性检出率,CEA以腺型最高(69.7%),Pro-GRP以小细胞型最高(76.9%),CYFRA21-1以鳞型最高(80.5%),β2-MG以鳞型最高(51.2%);四项联检对肺癌诊断的敏感性和准确性可提高到94.8%和90....     

肺癌患者手术前后血清NSE、CYFRA21-1、CEA的变化及临床意义

目的 探讨血清神经元烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)及癌胚抗原(CEA)在肺癌患者手术前后的水平变化及临床意义.方法 选择肺癌患者105例,肺良性病变患者54例.采用电化学发光法检测了手术前后血清NSE、CYFRA21-1、CEA水平.结果 肺癌组血清NSE和CYFRA21-1、CEA水平高于胃良性疾病组,差异有统计学意义(P<0.01).肺癌患者行根治性手术组术后血清NSE、CYFRA21-1、CEA水平明显低于手术前,差异有统计学意义(P<0.01).结论 手术切除肿瘤特别是行根治性切除术后,血清NSE、CYFRA21-1、CEA水平显著降低,动态观察NSE、CYFRA21-1、CEA水平及其变化,对肺癌的辅助诊断、预后判断有重要的价值.     

CEA、NSE、CYFRA21-1、ProGRP联合检测在肺癌诊断中的临床价值

目的探讨血清癌胚抗原(CEA)、特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)、神经元胃泌素释放肽前体(ProGRP)肿瘤标志物联合检测在肺癌诊断中的应用价值。方法以618例肺癌患者(342例腺癌患者、184例鳞癌患者、92例小细胞肺癌患者)和101例肺良性疾病患者,83例健康体检者共同为观察对象,分别检测血清CEA、CYFRA21-1、NSE、和ProGRP水平。结果肺癌组4种标志物水平显著高于肺良性疾病组和健康对照组,差异有统计学意义(P0.05)。腺癌患者血清CEA水平明显高于鳞癌、非小细胞肺癌和小细胞肺癌,差异有统计学意义(P0.05)。鳞癌CYFRA21-1较腺癌和小细胞肺癌高,差异有统计学意义(P0.05)。ProGRP水平小细胞肺癌组显著高于鳞癌和腺癌组,差异有统计学意义(P0.05)。通过四个项目的联合检测诊断肺腺癌、肺鳞癌、小细胞肺癌的各项指标敏感度可提高为85.38%、86.95%、94.56%,明显高于单一标志物检测,但特异性不及某些标志物单一检测。结论肿瘤标志物联合检测在肺癌筛查中应用价值较高,能明显提高肺癌的检出率,有利于肺癌的早期诊断,可以广泛应用于临床中。     

67例肺癌ECT全身骨显像及血清Cyfra21-1、NSE、CEA、CA125联合测定分析

目的探讨肿瘤标志物Cyfra21-1、NSE、CEA、CA125与肺癌骨转移及转移程度之间的相关性。方法 ECT骨显像采用西门子e.cam SPECT,~(99m)TC-MDP为显像剂,67例确诊为肺癌的患者全部行ECT骨显像;采用罗氏电化学发光分析仪(Cabas6000.e 601)对30例健康者、33例肺结核患者及67例肺癌患者进行了血清肿瘤标志物Cyfra21-1、NSE、CEA、CA125联合测定。分析了肺癌骨转移与肿瘤标志物间的关系。结果肺癌血清肿瘤标志物Cyfra21-1、NSE、CEA、CA125明显高于肺结核及健康对照组;P0.01。胸水中的Cyfra21-1、NSE测定值明显高于血清值;肺癌肿瘤标志物与肺癌病理类型之间有一定相关性,鳞癌Cyfra21-1为(71.45±22.81)ng/mL明显高于其他肺癌组P0.01。小细胞肺癌NSE测定值为(98.67±36.54)ng/mL,明显高于其他肺癌组,P0.01;67例肺癌未发生明显骨转移征象者33例,占49.3%;发生不同程度骨转移者34例,占50.7%;其中发生1～2处骨转移者14例,占20.9%;广泛骨转移者20例,占29.9%。腺癌骨转移发生率最高,达64%,其次是小细胞肺癌和鳞癌;肺癌骨转移程度与肿瘤标志物浓度有一定关系,广泛骨转移者Cyfra21-1和NSE测定值局限转移未转移者。结论肺癌骨转移及骨转移的程度与肿瘤标志物的表达程度有一定的相关性,多发骨转移常伴有明显的肿瘤标志物异常。肿瘤标志物Cyfra21-1有利于非小细胞性肺癌的检出,尤其是鳞癌的检出;NSE则有利于小细胞性肺癌的检出。联合测定Cyfra21 1、NSE、CEA、CA125大大提高了肿瘤检查的阳性率、灵敏度和准确度。全身骨显像及肺癌肿瘤标志物的联合检查对于肺癌的诊断和鉴别诊断有重要的临床价值。     

67例肺癌ECT全身骨显像及血清Cyfra21-1、NSE、CEA、CA125联合测定分析

Objective To explore the correlation between Cyfra21-1、 NSE、 CEA、CA125 and the bone metastasis in lung cancer.Methods Images were obtained on a gamma camera (E.CAM,Siemens,Erlangen,Germany)using 99mTC-MDP as a skeletal imaging agent.67 cases diagnosed as lung cancer were performed by ECT bone imaging,serum concentration of Cyfra21-1,NSE,CEA and CA125 were measured among 30 healthy individual,33 patients with pulmonary tuberculosis and 67 patients with lung cancer by electrogenerated chemiluminescence(ECL) (Roche,Germany).Results The serum Cyfra21-1、NSE、CEA、CA125 from lung cancer were higher than that of controls group and pulmonary tuberculosis group(P<0.01).and the pleural Cyfra21-l and NSE were significantly higher than that in serum.In lung cancer,there are correlation between tumor marker and its pathological types.Cyfra21-1 concentration in squamous cell carcinoma were significantly higher than that of other lung cancers(P<0.01),NSE level in small cell lung cancer were significantly higher than that other lung cancers(P<0.01).33 patients with lung cancer had no obvious sign of bone metastases among 67 cases (accounting for 49.3%),34 patients had bone metastases with varying degrees(accounting for 50.7 % ) ;Adenocarcinoma has highest incidence of bone metastasis( 64 % ),followed by small cell lung cancer and squamous cell carcinoma.Cyfra21-land NSE level is highest in cases with wide spread bone metastasis,followed by those with part bone metastasis and without bone metastasis in turn.Conclusion There are relationship between tumor marker and bone metastasis of lung cancer.Multiple bone metastases often were accompanied by obvious change of serum tumor marker.Cyfra21-lis a useful tool in diagnosis of non-small cell lung cancer,especially in squamous cell carcinoma.NSE is useful to identify the small cell lung cancer.Combined determination of Cyfra21-1,NSE,CEA and CA125 can improve sensitivity,accuracy and positive rate of diagnosis lung cancer.It seems that the whole body bone imaging combined Cyfra21-1,NSE,CEA and CA125 detection have important clinical value in diagnosis and identification of lung cancer.     

67例肺癌ECT全身骨显像及血清Cyfra21-1、NSE、CEA、CA125联合测定分析

Objective To explore the correlation between Cyfra21-1、 NSE、 CEA、CA125 and the bone metastasis in lung cancer.Methods Images were obtained on a gamma camera (E.CAM,Siemens,Erlangen,Germany)using 99mTC-MDP as a skeletal imaging agent.67 cases diagnosed as lung cancer were performed by ECT bone imaging,serum concentration of Cyfra21-1,NSE,CEA and CA125 were measured among 30 healthy individual,33 patients with pulmonary tuberculosis and 67 patients with lung cancer by electrogenerated chemiluminescence(ECL) (Roche,Germany).Results The serum Cyfra21-1、NSE、CEA、CA125 from lung cancer were higher than that of controls group and pulmonary tuberculosis group(P<0.01).and the pleural Cyfra21-l and NSE were significantly higher than that in serum.In lung cancer,there are correlation between tumor marker and its pathological types.Cyfra21-1 concentration in squamous cell carcinoma were significantly higher than that of other lung cancers(P<0.01),NSE level in small cell lung cancer were significantly higher than that other lung cancers(P<0.01).33 patients with lung cancer had no obvious sign of bone metastases among 67 cases (accounting for 49.3%),34 patients had bone metastases with varying degrees(accounting for 50.7 % ) ;Adenocarcinoma has highest incidence of bone metastasis( 64 % ),followed by small cell lung cancer and squamous cell carcinoma.Cyfra21-land NSE level is highest in cases with wide spread bone metastasis,followed by those with part bone metastasis and without bone metastasis in turn.Conclusion There are relationship between tumor marker and bone metastasis of lung cancer.Multiple bone metastases often were accompanied by obvious change of serum tumor marker.Cyfra21-lis a useful tool in diagnosis of non-small cell lung cancer,especially in squamous cell carcinoma.NSE is useful to identify the small cell lung cancer.Combined determination of Cyfra21-1,NSE,CEA and CA125 can improve sensitivity,accuracy and positive rate of diagnosis lung cancer.It seems that the whole body bone imaging combined Cyfra21-1,NSE,CEA and CA125 detection have important clinical value in diagnosis and identification of lung cancer.     

肺癌患者胸水和血清中细胞角蛋白19片段、神经元特异性烯醇化酶和肿瘤相关抗原72-4测定的临床价值

目的探讨胸水和血清中细胞角蛋白19片段(CYFRA21-1)、神经元特异性烯醇化酶(NSE)和肿瘤相关抗原(CA)72-4测定对肺癌的诊断和鉴别诊断价值。方法采用电化学发光法测定61例肺癌、33例良性疾病患者胸水和血清中CYFRA21-1、NSE和CA72-4水平。结果癌性胸水中CYFRA21-1、NSE和CA72-4水平分别为(73.1±42.9)μg/L、(34.3±25.7)μg/L和(21.6±13.2)μg/L,显著高于癌性血清组(P<0.01)和良性胸水组(P<0.01),良性胸水中CYFRA21-1、NSE和CA72-4水平与良性血清组差异无统计学意义(P>0.05);癌性胸水中CYFRA21-1对肺鳞癌敏感,NSE对小细胞肺癌敏感,CA72-4对肺腺癌敏感。结论联合检测CYFRA21-1、NSE和CA72-4三种肿瘤标志物对诊断和鉴别诊断良、恶性胸水有重要临床价值。     

联合检测血清CEA、CA125、NSE与CYFRA21-1在肺癌诊断中的临床意义

目的 通过检测肿瘤标志物CEA、CA125、NSE、CYFRA21-1在肺癌患者血清中的水平,探讨其在肺癌鉴别诊断中的价值.方法 采集肺癌组132例,肺良性病变组87例,健康对照组86例患者的静脉血,处理后得到血清,采用Elecsys2010电化学发光法测定4项肿瘤标志物的水平,分析肺癌组中各肿瘤标志物在血清中的含量以及单项检测、联合检测的敏感性和特异性.结果 肺癌组CEA、CA125、NSE、CYFRA21-1血清水平分别明显高于肺良性病变组和正常对照组,差异有统计学意义(P＜0.05).肺良性病变组和对照组比较,血清CA125、CEA差异有统计学意义(P＜0 05).腺癌患者血清CEA水平明显高于小细胞癌患者(P＜0.01);鳞癌患者血清CYFRA21-1水平明显高于小细胞癌(P＜0.05)与腺癌(P＜0.05);小细胞癌患者NSE水平明显高于腺癌和鳞癌(P＜0.01);腺癌患者CA125水平明显高于鳞癌和小细胞癌(P＜0.05).4项血清标记物联合检测的阳性率(97.0％)显著高于各单项的敏感性.结论 CEA、CA125、NSE与CYFRA21-1对不同组织类型肺癌均有一定的诊断价值,联合检测可大大提高灵敏度,对肺癌的早期诊断和鉴别具有重要意义.     

胸水与血清CYFRA21-1、CEA、NSE测定对肺癌的诊断价值

目的　探讨胸水和血清肿瘤标志物癌胚抗原 (CEA)、神经元特异性烯醇化酶 (NSE)、细胞角蛋白 19片段(CYFRA2 1- 1)在肺癌诊断中的临床价值。方法　采用电化学发光法测定 6 4例肺癌、36例良性肺病 (BLD)患者胸水和血清中CEAA、NSE、CYFRA2 1- 1水平。结果　肺癌患者血清中CEA、CYFRA2 1- 1、NSE的测定值分别为 34.99± 70 .5 2ng/ml、2 0 .5 7±2 8.8ng/ml、36 .2 1± 4 9.19ng/ml;而胸水中分别为 2 2 5 .36± 4 0 7.4 9ng/ml、134.38± 2 6 3.0 0ng/ml、74 .2 2± 119.0 5ng/ml,各项指标的统计学检验均有显著差异 (p <0 .0 1)。三者联合检测在胸水与血清中的阳性率分别为 98.4 4 %和 81.2 5 %。胸水中CEA、CYFRA2 1- 1和NSE在腺癌、鳞癌及非小细胞性肺癌的阳性率 (分别为 83.14 %、95 %、10 0 % )高于血清 (分别为 6 4 .2 9%、80 %、75 % )。结论　胸水CEA、NSE、CYFRA2 1- 1检测对肺癌的诊断价值优于血清     

CYFRA21-1、NSE、CEA和CA125检测在肺癌诊断中应用探讨

目的 探讨神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原125(CA125)联合测定对肺癌的诊断价值。方法 应用化学发光波对62例肺癌及30名健康人血清进行检测。结果 神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原125(CA125)水平及检测阳性率均明显高于良性肺病及正常对照组(P<0.01)。鳞癌、腺癌和小细胞肺癌分别以CYFRA21-1、CEA、NSE升幅较为明显。结论 神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原125(CA125)联合检测可明显提高肺癌的阳性检出率和检测特异性,对肺癌的早期诊断、疗效监测、预后判断有重要意义。     

血清CYFRA21-1、NSE联合检测对肺癌诊断的临床意义

目的 探讨血清CYFRA21-1与NSE联合检测对肺癌的诊断价值。方法 应用电化学发光免疫分析技术测定77例肺癌患者、22例肺部良性疾病患者和120例健康对照组血清CYFRA21—1、NSE的水平。结果肺癌患者血清CYFRA21-1、NSE水平明显高于肺部良性疾病组和健康对照组（P〈0．01）。CYFRA21-1在肺鳞癌中表达水平最高，NSE在肺小细胞癌中表达水平最高。血清CYFRA21-1＋NSE联合检测肺癌的敏感性为68．8％，特异性为86．6％，准确性为80．4％。结论 检测血清CYFRA21—1与NSE对肺癌诊断具有重要的临床参考价值，联合检测CYFRA21-1＋NSE可提高肺癌检测的敏感性和准确性，并为肺癌的早期诊断、疗效监测、预后判断提供依据。